United States: Medical Devices And Cybersecurity: FDA Calls For Comprehensive Risk Management Programs

The Food and Drug Administration (FDA), with the issuance of its recent 2016 Draft Guidance "Postmarket Management of Cybersecurity in Medical Devices," continues to step up its involvement with medical devices having a software component. This is consistent with the Office of Inspector General's 2016 Work Plan, wherein the OIG specifically intends to focus on the vulnerability of networked, as well as software-driven medical devices.

This is just the latest move in the FDA's focus on medical device software, which began as early as 2002, when the agency published its Guidance on Software Validation. Since that time, the use of software in medical devices has increased and become more complex. This has coincided with the emergence of the mobile medical app industry. This market growth, along with the growing sensitivity on cyber safety, has caused the FDA to turn its attention to cybersecurity and protecting public health from vulnerabilities presented by the increasing use of software in medical devices.

Premarket management of cybersecurity

The FDA has approached the management of cybersecurity risks from both a premarket position, as well as a postmarket management perspective. In October 2014, the FDA published a Guidance entitled "Content of Premarket Submissions for Management of Cybersecurity in Medical Devices," which aimed at assisting companies submitting 510(k) premarket notifications, Premarket Approvals (PMA), Product Development Protocols (PDPs) and Humanitarian Device Exemption (HDE) submissions to ensure that all such submissions adequately address cybersecurity considerations. This guidance suggests that entities filing a premarket submission with the FDA include the following components in the filings:

  • Identification of cybersecurity assets, threats and vulnerabilities 
  • Assessment of the impact of these threats and vulnerabilities on device functionality and the consumer, customer or patient
  • Assessment of the likelihood of a threat or vulnerability being exploited
  • A determination of the risks levels and suitable mitigation strategies
  • An assessment of residual risk and risk acceptance criteria

This list is not all inclusive, and each point requires a consideration of the nature and function of the device that is subject to the premarket submission. The FDA has implemented a risk-based approach to these analyses. In these submissions, medical device manufacturers are directed to consider cybersecurity risks, assess the vulnerabilities and identify how they will protect against exploitation of those vulnerabilities. The submissions should include preemptively designed measures that proportionally deal with the identified vulnerabilities, the risk those vulnerabilities pose if exploited, and the potential impact on consumers or patients. The FDA recommends that medical device companies spend a significant amount of time in their submissions addressing these vulnerabilities while justifying all controls and mitigating efforts in light of the vulnerabilities and risks they address. In the analysis of these vulnerabilities, the FDA envisions that these analyses will be divided into two stages:

  1. Identify and Protect: Pre-emptive measures to identify possible vulnerabilities and proactively implement controls to reasonably prevent exploitation.
  2. Detect, Respond, Recover: These steps are implemented to respond when a vulnerability is exploited, responding to the exploit to minimize the risk to the device and the patient or user, and recover information from the device so that further exploitation can be prevented.

Under this final Guidance, premarket submissions require manufacturers and developers to possess a significant understanding of how their products will be used in the market, what access is available to those devices for vulnerability exploitation, and how they can properly address these issues during the design of the product itself. Since the inception and finalization of this premarket submission guidance, the FDA has further examined the role of cybersecurity and developed/adopted industry vocabulary and applied it to susceptible medical devices.

A new postmarket guidance scheme, a new vocabulary

As the FDA has considered the issue of cybersecurity, it has refined the risk-based concepts by dealing with risks in ways proportional to their potential impact. The FDA has accomplished this by drafting another guidance, yet to be finalized, which it issued on Jan. 22, 2016 wherein it addresses Postmarket Management of Cybersecurity in Medical Devices. The FDA's approach, as reflected in this draft Guidance, is evidenced in a new set of terms the FDA has defined in order to help the industry deal with cybersecurity issues with a clear set of parameters. Among the most important concepts are:

  • Compensating Controls: A safeguard or countermeasure external to the device employed by the end user in the place of sufficient controls implemented by the manufacturer. These Compensating Controls provide sufficient protection for the medical device such that it is not necessary for the control to be implemented within the device itself. Compensating Controls may be used for a variety of reasons, but the FDA envisions them being used where it is more efficient for the end user to provide the control rather than the manufacturer.
  • Cybersecurity Routine Updates and Patches: Medical devices, like any other piece of modern technology, utilize firmware and software that may contain bugs or vulnerabilities that the manufacturer must fix via patches or updates. They may also impact the product instructions for use and labeling. Generally, these are not considered a repair and are not required to be reported to the FDA. Not included are those updates, patches or repairs that are associated with a reasonable probability that use of or exposure to the medical device will cause serious adverse health consequences or death.
  • Controlled Risk: A risk is considered controlled when steps taken by the manufacturer, through capabilities of the device itself or through Compensating Controls, are effective such that there is sufficiently low risk that the device's essential clinical performance could be compromised by a cybersecurity vulnerability. A risk becomes an Uncontrolled Risk where there exists an unacceptable risk that the device could be so compromised as to impair its essential function.
  • Cybersecurity Signal: A Cybersecurity Signal is any indication or information that indicates the potential for or confirmation of a cybersecurity vulnerability or exploit that could affect a medical device. Such signals may include internal monitoring, business partners, postmarket surveillance, customer complaints, researchers and Information Sharing and Analysis Organizations (or ISAOs).
  • Essential Clinical Performance: Performance levels necessary to achieve freedom from unacceptable clinical risk as defined by the manufacturer. If the Essential Clinical Performance is compromised, users may be exposed to harm or may require intervention to prevent that harm.
  • Exploit, Threat, Vulnerability: The FDA has defined several classes of risks to medical devices and software that result from vulnerabilities in the software that may be exploited, intentionally or unintentionally, and represent a threat to the essential clinical performance of the medical device or software. It is this three-step system of risk identification that the FDA's cybersecurity efforts revolve around.
  • Remediation: Any action taken to reduce the risk to a medical device or software's essential clinical performance. These may include through patches and updates or compensating controls. Complete remediations are actions that entirely address a risk to sufficiently categorize it as a Controlled Risk. Any other remediation is considered an incomplete risk.

This draft guidance emphasizes the FDA's concerns about the risk to medical devices and therefore public health when medical device manufacturers and health care providers are not vigilant as to cybersecurity vulnerabilities and breaches. This then is what has led to the FDA's recommendation within the draft Guidance that medical device manufacturers implement a "comprehensive cybersecurity risk management program." These programs will have to be designed to include a reporting requirement for the most serious risks that pose safety issues, as well as a patching requirement for the less serious risks. Critical components of each of these management programs will have to include: monitoring; assessing and detecting risks; handling of the vulnerabilities once identified or realized; and mitigation strategies to respond and recover from cybersecurity breaches.

The filing of premarket submissions for medical devices which carry a cybersecurity risk, as well as the drafting of the postmarket management plan noted above, require the involvement of experienced regulatory counsel in coordination with cybersecurity counsel. Thompson Coburns' Life Science and Cybersecurity practices have a coordinated approach in assisting our medical device clients in complying with not only these regulatory requirements, but assisting them in responding should a cybersecurity breach occur. If you have any questions about cybersecurity matters, or any other content on this blog, contact the authors at Thompson Coburn where we have attorneys experienced in medical device compliance, FDA compliance programs, cybersecurity breaches and related counselling.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
Horne LLP
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Horne LLP
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions